November 18, 2013 / 11:26 AM / in 4 years

BRIEF-Cell Therapeutics expects to get $67 mln in cash milestone payments from Baxter through 2015 - SEC filing

Nov 18 (Reuters) - Cell Therapeutics Inc : * Expects could pay up to $96 million in development costs for persist-1 & 2

myelofibrosis & acute myeloid leukemia programs till mid-2017 * Under Baxter deal co expects to receive $67 million in cash milestone

progress payments from Baxter through 2015 - SEC filing * Source text for Eikon * Further company coverage

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below